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BRAF and MEK inhibitors have improved outcomes for patients with BRAF-mutant 
melanoma, but their efficacy is limited by both intrinsic and acquired resistances. 
Activation of the PI3K pathway can mediate resistance to these agents, providing a 
strong rationale for combination therapy in melanoma. Here, a panel of nine low-pas-
sage human metastatic melanoma cell lines with BRAF mutations was tested in cell 
proliferation and protein expression assays for sensitivity to inhibitors of MEK (selu-
metinib) and BRAF (vemurafenib) as single agents and in combination with inhibitors 
of pan-PI3K (ZSTK474), pan-PI3K/mTOR (BEZ235), individual PI3K isoforms (p110α, 
A66; p110β, TGX-221; p110γ, AS-252424; p110δ, idelalisib), or mTORC1/2 (KU-
0063794). Selumetinib and vemurafenib potently inhibited cell proliferation in all cell 
lines, especially in those that expressed low levels of phosphorylated AKT (pAKT). 
ZSTK474 and BEZ235 also inhibited cell proliferation in all cell lines and enhanced 
the antitumor activity of selumetinib and vemurafenib in the majority of lines by either 
interacting synergistically or additively to increase potency or by inducing cytotoxicity by 
significantly increasing the magnitude of cell growth inhibition. Furthermore, ZSTK474 
or BEZ235 combined with selumetinib to produce robust inhibition of pERK, pAKT, and 
pS6 expression and synergistic inhibition of NZM20 tumor growth. The inhibitors of 
individual PI3K isoforms or mTORC1/2 were less effective at inhibiting cell proliferation 
either as single agents or in combination with selumetinib or vemurafenib, although 
KU-0063794 synergistically interacted with vemurafenib and increased the magnitude 
of cell growth inhibition with selumetinib or vemurafenib in certain cell lines. Overall, 
these results suggest that the sensitivity of BRAF-mutant melanoma cells to BRAF or 
MEK inhibitors is at least partly mediated by activation of the PI3K pathway and can 
be enhanced by combined inhibition of the BRAF/MEK and PI3K/mTOR signaling 
pathways.
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introduction
BRAF mutations leading to constitutive activation of the RAS/
RAF/MEK/ERK pathway and increased cell cycle progression, dif-
ferentiation, survival, migration, and angiogenesis are reported in 
40–50% of melanoma cases (1). Therapeutic agents that selectively 
target BRAF (e.g., vemurafenib, dabrafenib) or its downstream 
substrate MEK (e.g., trametinib) can improve overall survival in 
BRAF-mutant metastatic melanoma patients (2–5); however, their 
use as monotherapy is limited by intrinsic and acquired resistance. 
While the majority (around 80%) of BRAF-mutant melanomas 
display some degree of tumor regression upon initial treatment 
with BRAF or MEK inhibitors, approximately 50% fail to meet 
threshold criteria for partial response and only 2–3% respond 
completely, implying a degree of intrinsic resistance in the majority 
of BRAF-mutant melanomas (2, 3, 6). Acquired resistance is also 
a major problem during treatment with BRAF or MEK inhibi-
tors, with most patients demonstrating tumor progression within 
5–7 months of the start of therapy (2, 7).
Among the multiple potential mechanisms of intrinsic and 
acquired resistance to BRAF and MEK inhibition that have been 
identified (8–14), the PI3K signaling pathway has been frequently 
implicated. Loss of functional PTEN occurs in 10–30% of mela-
nomas, preventing negative regulation of PI3K activity, resulting 
in hyperactivation of AKT and, subsequently, in increased cell 
survival, proliferation, migration, and invasion (15). PTEN loss has 
been implicated in intrinsic resistance to both vemurafenib (16) 
and dabrafenib (17). Similarly, high expression of phosphorylated 
AKT (pAKT) appears to predict resistance to the MEK inhibitor 
selumetinib in melanoma patients (18) and to selumetinib and 
vemurafenib in cell lines (19–21). Reactivation of ERK signaling 
in the presence of inhibitor through mechanisms such as MEK1 
or NRAS mutation, dimeric RAF signaling, BRAF amplification, 
or COT upregulation (1, 8, 9, 11, 12) is the primary route for 
acquired resistance. Whole-exome sequencing has revealed that 
ERK reactivation mechanisms are present in 50–70% of tumors 
from drug-resistant patients, with multiple resistance mechanisms 
detected in some tumors (21, 22). Non-ERK-dependent acquired 
resistance can also arise through activation of the PI3K pathway 
by genetic alteration (21) or upregulation of growth factor recep-
tors such as the platelet-derived growth factor receptor or the 
insulin-like growth factor receptor (19, 23, 24). Furthermore, 
persistent activity of mTORC1, which operates downstream of 
both the PI3K and RAS/RAF/MEK/ERK signaling pathways, can 
lead to resistance following BRAF or MEK inhibition (19, 25, 26). 
Conversely, compensatory signaling through the RAS/RAF/MEK/
ERK pathway following receptor tyrosine kinase (RTK) upregula-
tion may promote resistance to PI3K pathway inhibition (27–30).
Given the evidence indicating that the RAS/RAF/MEK/ERK 
and PI3K pathways co-operate in melanomagenesis, the extensive 
cross-talk that exists between the pathways (31), and the role of each 
pathway in resistance to inhibition of the other, a strong rationale 
exists for combined pathway inhibition in melanoma. In support 
of this, several early-phase clinical trials are currently underway 
for combined PI3K and BRAF/MEK inhibitors in melanoma, while 
preclinical melanoma models have reported synergistic growth 
inhibition and overcoming of acquired or intrinsic resistance to 
BRAF or MEK inhibitors with PI3K pathway inhibitors (19, 24, 
32–35). However, few studies have assessed these combinations in 
the setting of intrinsic sensitivity to BRAF or MEK inhibitors in 
melanoma. Here, we selected a panel of low-passage BRAF-mutant 
melanoma cell lines that were established and maintained at 5% 
oxygen tension to mimic physiological oxygen concentrations and 
were sensitive to the MEK inhibitor selumetinib and the BRAF 
inhibitor vemurafenib. We evaluated the activity of individual 
or pan isoform inhibitors of PI3K and/or mTOR alone or in 
combination with selumetinib or vemurafenib in the cell line 
panel to investigate if inhibition of PI3K/mTOR signaling could 
enhance the antitumor activity of selumetinib or vemurafenib in 
BRAF-mutant melanoma.
Materials and Methods
chemicals
A66 (36), ZSTK474 (37), BEZ235 (38), TGX-221, and AS-252424 
(39) were synthesized at the Auckland Cancer Society Research 
Centre as previously described. Selumetinib (Selleck Chemicals 
and LC Laboratories), vemurafenib (Medkoo Biosciences), 
idelalisib (Symansis), and KU-0063794 (Selleck Chemicals) were 
supplied as indicated.
BEZ235 was prepared as a dimethanesulfonate salt by treating a 
suspension of the solid in methanol with 2.2 equivalents of meth-
anesulfonic acid, to give a clear solution. Dilution with ethyl acetate 
gave a precipitate, which was collected by filtration and washed 
with further ethyl acetate. Recrystallization from methanol–ethyl 
acetate gave the dimethanesulfonate salt as a pale yellow solid: mp 
283–286°C; 1H NMR (400 MHz, DMSO-d6) δ 9.49 (s, 1H), 8.86 
(d, J = 2.3 Hz, 1H), 8.52 (d, J = 2.1 Hz, 1H), 8.47 (dd, J = 9.0, 
1.9 Hz, 1H), 8.39 (d, J = 9.0 Hz, 1H), 8.06–8.09 (m, 2H), 7.95–7.99 
(m, 2H), 7.85–7.90 (m, 3H), 7.73 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 
7.37 (d, J = 1.7 Hz, 1H), 4.85 (br, exchangeable with D2O, 2H), 
3.70 (s, 3H), 2.39 (s, 6H), 1.79 (s, 6H); Combustion Analysis, Calc. 
for C32H31N5O7S2: C, 58.1; H, 4.7; N, 10.6. Found: C, 58.0; H, 4.6; 
N, 10.65%.
cell culture
A panel of nine melanoma cell lines was chosen from a series 
of lines generated from surgical samples of metastatic melanoma 
obtained with appropriate consent from patients throughout New 
Zealand as previously described (40). The cell lines were maintained 
in α-modified minimal essential medium (Life Technologies) 
supplemented with insulin (5 μg/ml), transferrin (5 μg/ml), and 
sodium selenite (5 ng/ml; Roche Applied Sciences), 100 U/ml of 
penicillin, 100 μg/ml of streptomycin (Life Technologies), and 5% 
fetal calf serum (Moregate Biotech). The cell lines were cultured 
under low-oxygen conditions (5% O2, 5% CO2) at 37°C.
gene Mutation Profiling
The mutation status of 32 common driver oncogenes and hTERT 
was determined in the melanoma cell lines by Sequenom analysis. 
DNA was extracted using PureLinkTM Genomic DNA kit (Life 
Technologies), according to manufacturer’s protocol. To remove 
the EDTA-based elution buffer, DNA was re-precipitated into 
milliQ water. This was achieved by addition of ethanol and 
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5M ammonium acetate at −80°C for 2  h and centrifugation 
at 18,000 × g for 30 min at 4°C. The pellet was resuspended in 
ethanol and re-centrifuged at 18,000 × g for 10 min at 4°C, prior 
to resuspension in milliQ water. Extracted DNA was evaluated 
for gene mutations on the Sequenom MassARRAY® using the 
MassARRAY OncoCartaTM Panel v 1.0 and the MelaCartaTM Panel 
v1.0 plus hTERT, according to manufacturer’s protocol. Analysis 
was carried out using Sequenom MassARRAY Typer Analyzer 
4.0 genotyping software. PTEN mutation status was determined 
by PCR sequencing as described previously (41).
cell Proliferation
Cells were seeded into 96-well plates at 10,000 cells per well and 
left to settle for 24 h at 37°C with 5% CO2 and 5% O2. Compounds 
were added to each plate at a range of concentrations in 0.2% 
or less DMSO. For combination studies, both compounds were 
tested at equivalent concentrations. Plates were returned to the 
incubator for 72 h before fixing in 10% trichloroacetic acid at 4°C 
for 1 h and staining with 0.4% sulforhodamine B (Sigma-Aldrich) 
in 1% acetic acid for 30 min in the dark at room temperature. 
Plates were washed in 1% acetic acid, dried, and incubated with 
unbuffered Tris base (10 mM; Serva) for 30 min on a plate shaker 
in the dark to solubilize the stain. The plates were read on a BioTek 
EL808 microplate reader at an absorbance of 490 nm with a refer-
ence wavelength of 450  nm. Absorbances of treated cells were 
compared to untreated cells at 0 h (100% growth inhibition) and 
72 h (0% growth inhibition) after treatment. Growth inhibition 
above 100% indicated that fewer cells were present than when the 
compounds were first administered. EC50 values were calculated 
by fitting the inhibition data to a four-parameter logistic sigmoidal 
dose–response curve using GraphPad Prism 6.01. Combination 
indices (CI) were calculated at EC50 using the method of Chou and 
Talalay (42). CI values <0.7 indicated synergy, 0.7–0.9 indicated 
weak synergy, 0.9–1.1 indicated additivity, 1.1–1.45 indicated weak 
antagonism, and >1.45 indicated antagonism.
Western Blotting
Untreated cells for basal protein expression or cells treated with 
500 nM of compound for 1 or 24 h were lysed in lysis buffer con-
taining 1% protease inhibitor cocktail (Sigma-Aldrich) on ice for 
15–30 min. Cells were centrifuged at 13,000 rpm for 10 min at 4°C 
to remove insoluble material. Protein concentration of cell lysates 
was determined by bicinchoninic acid assay (Thermo Scientific) 
against bovine serum albumin (BSA; Immuno-Chemical Products 
Ltd.) standards at an absorbance of 562 nm on a BioTek Synergy 
HT plate reader using KC4 v3.4 software. Forty micrograms of each 
lysate was loaded onto polyacrylamide gels (10% acrylamide) and 
separated by SDS-PAGE at 120V for 90 min. Each gel was trans-
ferred onto an Immobilin® PVDF membrane (Sigma-Aldrich) at 
25V for 12 min on a BioRad Trans-Blot® TurboTM semi-dry transfer 
machine. Following protein transfer, membranes were incubated in 
blocking buffer [Tris-buffered saline with 0.5% Tween®-20 (Serva) 
and 3% BSA] for at least 30 min then cut and incubated overnight 
at 4°C with antibodies at 1:1000 dilution (unless indicated) against 
either pAKT (Ser473, Thr308), pERK1/2 (Thr202/Tyr204), pS6 
(Ser235/Ser236, 1:2000; Ser240/Ser244, 1:2000), AKT, ERK1/2, 
S6 (1:2000), PTEN (1:100), IGF1Rβ, EGFR, Insulin Receptor β, 
c-MET, ERBB3, MERTK (all Cell Signaling Technologies), and 
β-actin (1:2000; Sigma-Aldrich). Membranes were washed then 
incubated with anti-mouse (1:20,000; Sigma-Aldrich) or anti-
rabbit (1:4000–5000; Dako) goat IgG HRP-conjugated secondary 
antibody in blocking buffer for 1 h at room temperature. After fur-
ther washes, the membranes were incubated with BioRad ClarityTM 
ECL or Perkin Elmer Western Lighting Ultra (pAKT membranes) 
for 4  min prior to imaging on a LAS-4000 luminescent image 
analyzer (Fujifilm). After visualization of phosphorylated proteins, 
membranes were stripped and reprobed with total proteins and 
β-actin. β-actin was used to confirm equal protein loading in 
each blot. Each cell lysate was tested in duplicate in two to three 
independent experiments.
Tumor growth inhibition in nZM20 Xenograft 
Model
Age-matched specific pathogen-free female NIH-III mice were 
subcutaneously inoculated with 5 × 106 NZM20 cells. Treatment 
was initiated when tumors reached 150 mm3 in volume as meas-
ured by electronic calipers. The dosing vehicles used were 0.5% 
hydroxypropyl methylcellulose with 0.2% Tween 80 (selumetinib 
and control vehicle), 2% carboxymethylcellulose with 1% Tween 
80 (ZSTK474), and 40% PEG-400 in 20% hydroxypropyl-β-
cyclodextrin (BEZ235). All vehicle constituents were supplied by 
Sigma-Aldrich. Treatments were administered daily for 14 days 
at half the single agent maximum tolerated dose as the free base 
equivalent by oral gavage at a volume of 10 ml/kg. Animals were 
monitored daily for bodyweight and any observational signs of 
toxicity. Tumor growth inhibition (TGI) was calculated by deter-
mining the tumor size of drug-treated mice relative to starting 
size as a percentage of the average relative tumor size of control 
mice. Synergy was inferred if the TGI of the combination was 
greater than the product of the TGI values of each single agent. All 
animal experiments followed protocols approved by the University 
of Auckland Animal Ethics Committee.
results
Mutation status and Protein expression of 
BRAF-Mutant Melanoma cell line Panel
We selected a panel of nine early passage BRAF-mutant melanoma 
cell lines that were both developed and maintained at low-oxygen 
tension (5%). The mutation status of common oncogenic driver 
mutations in these lines was determined by Sequenom or PCR 
profiling. Seven of the cell lines contained V600E mutations in 
BRAF, while two contained V600K mutations (Table 1). Three 
lines contained confirmed frameshift mutations or deletions in 
PTEN and five lines had C250T or C228T mutations in hTERT. 
No mutations were detected in ABL1, AKT1, AKT2, AKT3, CDK4, 
CTNNB1, CXCR4, EGFR, EPHA10, EPHB6, ERBB2, ERBB4, 
FGFR1, FGFR3, FLT3, GNA11, GNAQ, HRAS, JAK2, KIT, KRAS, 
MEK, MET, NEK10, NRAS, PDGFA, PDGFRA, PIK3CA, PTK2B, 
RET, and ROR2.
The basal protein expression of phosphorylated and/or total 
forms of AKT, PTEN, ERK1/2, and S6 were determined in the 
cell line panel by western blotting (Figure 1). Minor differences 
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in basal expression were detected between different lysates of the 
same cell line (e.g., compare Figure 1 to control lysates in Figures 5 
and 6), but generally the same pattern of expression was evident. 
pAKT was variably expressed across the cell line panel with similar 
expression at ser473 and thr308 phosphorylation sites. Cell lines 
with low to moderate pAKT expression had high-PTEN expres-
sion (NZM3, NZM11, NZM12, and NZM20), unless they were 
PTEN-mutant (NZM34, NZM43). All PTEN-mutant lines, along 
with NZM30, lacked PTEN expression. pERK was expressed in 
all cell lines at variable levels, with the lowest expression detected 
in NZM7 and NZM43, while pS6 was expressed in all cell lines at 
similar levels relative to total protein.
TaBle 1 | gene mutation status of BRAF, PIK3CA, PTEN, and hTERT and 
protein expression of PTen and paKT in the melanoma cell line panel.
cell line Mutation status Protein expression
BRAF PIK3CA PTEN hTERT PTen paKT
NZM3 V600K WT WT WT +++ +/−
NZM6 V600E WT Exon 3  
deletion
WT − +++
NZM7 V600E WT WT C250T +++ ++
NZM11 V600E WT WT WT +++ +/−
NZM12 V600E WT WT C250T +++ ++
NZM20 V600E WT WT C228T +++ +/−
NZM30 V600E WT WT (exons 
2–9) Exon 1 
unknown
C228T − +++
NZM34 V600E WT Exon 5 
frameshift
C250T − ++
NZM43 V600K WT Exon 1 
frameshift
WT − ++
WT, wild type; +++, high expression; ++, moderate expression; +, low expression; 
+/−, not expressed in some blots and low expression in others; −, not expressed  
in all blots.
Several RTKs that can activate PI3K/mTOR or RAS/RAF/
MEK/ERK signaling pathways were expressed in the NZM lines 
(Figure 1). High-EGFR expression was observed in NZM7 and 
NZM12, which may have accounted for the moderate to high 
pAKT expression in these two lines, despite the expression of 
PTEN. The low expression of RTKs (apart from c-MET) in NZM43 
may explain why pERK and pAKT signaling was relatively low 
in this line compared to the other BRAF-mutant and PTEN-null 
cell lines.
BRAF-Mutant Melanoma lines with low-paKT 
expression are More sensitive to selumetinib 
and Vemurafenib
Each cell line in the panel was exposed to multiple concentra-
tions of selumetinib or vemurafenib to determine the effects of 
these drugs on cell proliferation. Selumetinib was highly effec-
tive at inhibiting cell proliferation in all cell lines, with EC50’s 
ranging from 12.0 ± 3.7 to 131 ± 56 nM (Figure 2A). The lowest 
EC50 values were observed in low-pAKT-expressing cell lines 
NZM3, NZM11, NZM20, and NZM43. Similarly, vemurafenib 
effectively inhibited cell proliferation in all cell lines, generating 
EC50 values <20 nM in NZM3, NZM11, and NZM20. However, 
vemurafenib was almost 100-fold less potent than selumetinib 
in NZM43 cells (EC50 =  2.1 ±  1.2 μM vs. 24.2 ±  10.1  nM). 
There was no clear relationship between basal pERK protein 
expression and selumetinib or vemurafenib sensitivity in the 
cell line panel.
Since BRAF and MEK inhibitors have recently shown promise 
as combination therapy for BRAF-mutant melanoma (5), the 
effectiveness of selumetinib and vemurafenib in combination at 
preventing cell proliferation was also determined. All cell lines, 
except NZM7 and NZM43, the two with lowest basal pERK expres-
sion, showed synergistic interactions at EC50 when the drugs were 
FigUre 1 | Basal expression of key signaling molecules and receptor tyrosine kinases involved in the Pi3K/mTOr and ras/raF/MeK/erK signaling 
pathways. Each blot is a representative image of two to three independent cell lysates.
FigUre 2 | selumetinib and vemurafenib potently inhibit cell 
proliferation in BRAF-mutant melanoma cell lines. (a) EC50 values  
for selumetinib, vemurafenib, and selumetinib + vemurafenib with 
combination interactions shown based on the CI values at EC50.  
(B) Growth profile for NZM11 and NZM34 cells treated with selumetinib  
or (c) vemurafenib. (D) Maximum inhibition of cell proliferation relative  
to pretreatment in NZM cell lines after 72 h exposure to selumetinib, 
vemurafenib or selumetinib, and vemurafenib at concentrations up to 
10 μM. Bars or symbols represent the mean ± SEM of n = 3–6. CI values 
<0.7 indicated synergy, 0.7–0.9 indicated weak synergy, 0.9–1.1 indicated 
additivity, 1.1–1.45 indicated weak antagonism, and >1.45 indicated 
antagonism.
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administered in combination (Figure 2A; Table 2). On examining 
the EC50 profiles, it became apparent that there was variability 
among the cell lines in the extent of proliferation that could be 
inhibited by selumetinib (Figure 2B) and vemurafenib (Figure 2C). 
In most cell lines, selumetinib and to a lesser extent vemurafenib at 
concentrations up to 10 μM were unable to inhibit cell proliferation 
by 100% back to pretreatment cell counts (Figure 2D). The major 
exceptions were low-pAKT-expressing NZM3 and NZM11, where 
both selumetinib and vemurafenib inhibited cell proliferation by 
>110 and >120%, respectively, indicating that the drugs had a 
TaBle 2 | combination indices at ec50 for the combination treatment 
groups relative to each single agent.
cell 
line
selumetinib 
+ Vemurafenib
selumetinib  
+ ZsTK474
selumetinib  
+ BeZ235
Vemurafenib  
+ ZsTK474
Vemurafenib 
+ BeZ235
NZM3 0.35 ± 0.07 0.92 ± 0.05 0.87 ± 0.12 0.92 ± 0.26 0.72 ± 0.25
NZM6 0.32 ± 0.09 0.91 ± 0.05 0.97 ± 0.05 0.46 ± 0.05 0.73 ± 0.17
NZM7 3.30 ± 1.23 2.47 ± 0.86 1.36 ± 0.38 0.24 ± 0.03 0.31 ± 0.03
NZM11 0.45 ± 0.05 0.81 ± 0.21 1.47 ± 0.35 1.58 ± 0.58 1.29 ± 0.20
NZM12 0.68 ± 0.27 0.91 ± 0.21 1.08 ± 0.09 0.36 ± 0.02 0.87 ± 0.12
NZM20 0.32 ± 0.07 0.99 ± 0.12 1.07 ± 0.07 1.02 ± 0.73 1.11 ± 0.27
NZM30 0.69 ± 0.43 1.38 ± 0.27 0.87 ± 0.04 0.65 ± 0.23 0.68 ± 0.05
NZM34 0.78 ± 0.14 1.28 ± 0.11 1.07 ± 0.11 0.60 ± 0.11 0.62 ± 0.15
NZM43 5.98 ± 2.53 1.89 ± 0.22 1.33 ± 0.32 0.37 ± 0.09 2.86 ± 1.13
Data are mean ± SEM (n = 3–5).
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cytotoxic response on these cell lines. Combining selumetinib and 
vemurafenib offered no significant increase in maximum inhibi-
tion in cell proliferation compared to both agents administered 
alone in any cell line, such that inhibition of proliferation failed 
to reach 100% in six of the nine cell lines.
ZsTK474 and BeZ235 can enhance the 
antiproliferative activity of selumetinib or 
Vemurafenib in BRAF-Mutant Melanoma cell 
lines
Since the antiproliferative activity of selumetinib and vemurafenib 
was less pronounced in BRAF-mutant melanoma cell lines that 
expressed pAKT, we investigated if inhibition of PI3K activity 
could promote growth inhibition in BRAF-mutant melanoma 
cell lines. To achieve this, the pan-PI3K inhibitor ZSTK474 and 
the dual PI3K/mTOR inhibitor BEZ235 were administered to the 
cell line panel either alone or in combination with selumetinib 
or vemurafenib. ZSTK474 effectively inhibited cell proliferation 
across the cell line panel with EC50’s ranging from 416 ± 211 to 
1278 ± 390 nM (Figure 3A); however, maximal inhibition only 
reached 100% in four out of nine cell lines at concentrations 
up to 10 μM (Figure 3B), indicating that ZSTK474 was unable 
to elicit a full cytostatic response in the majority of the NZM 
lines. Despite only modest synergy or additivity at EC50 in five 
lines when selumetinib and ZSTK474 were administered in 
combination (Figure  3A; Table  2), maximal inhibition was 
significantly increased relative to both single agents in all NZM 
lines (P  <  0.05) except NZM3, NZM7, and NZM11, where 
selumetinib or ZSTK474 alone inhibited growth by >105% 
(Figure 3B). As a result, growth inhibition exceeded 100% in 
all lines treated with selumetinib and ZSTK474 in combination, 
indicating a cytotoxic response. This response is evident in the 
growth curves for these agents in NZM34 (Figure 3C), where a 
weak antagonistic interaction was observed for the combination 
at EC50, yet maximum inhibition was significantly increased from 
82.3 ± 2.1 or 100.7 ± 3.0% with selumetinib or ZSTK474 alone 
to 120.5 ± 0.8% with the combination (P < 0.001 vs. both single 
agents).
BEZ235 was highly potent across the cell line panel with 
EC50’s ranging from 10.2 ± 2.8 to 163 ± 100 nM (Figure 3D) 
and was able to inhibit cell proliferation to a greater extent 
than either ZSTK474 or selumetinib with >100% inhibition 
observed in seven of nine cell lines (Figure  3E). Similarly to 
the combination of ZSTK474 with selumetinib, combining 
BEZ235 with selumetinib did not induce a synergistic interac-
tion in the majority of cell lines, although maximal inhibition 
was significantly increased relative to both single agents in five 
cell lines (P <  0.05), as shown for NZM34 (Figure  3F), such 
that maximal growth inhibition exceeded 100% in all cell lines 
treated with BEZ235 and selumetinib. The only cell lines that did 
not show a >10% increase in maximal growth inhibition with 
combination treatment relative to single agent treatment were 
NZM3 and NZM11, where growth inhibition exceeded 100% 
with selumetinib alone.
For vemurafenib, synergy (CI  <  0.7) was observed with 
ZSTK474 in the six cell lines that were least sensitive to vemu-
rafenib as a single agent (Figure 4A; Table 2), but significant 
changes in maximal inhibition were observed in only NZM7, 
NZM12, NZM34, and NZM43 (P  <  0.05) (Figures  4B,C). 
Likewise, vemurafenib and BEZ235 had a synergistic or weakly 
synergistic interaction in six cell lines, with the exceptions being 
NZM11, NZM20, and NZM43, which were highly sensitive 
(EC50 ≤ 10 nM) to either vemurafenib or BEZ235 as single agents 
(Figure 4D). Significant changes in maximum inhibition with 
this combination were limited to NZM6, NZM7, and NZM34 
(P < 0.05) (Figures 4E,F). Both vemurafenib combinations were 
able to inhibit cell proliferation by >100% in all cell lines.
selumetinib in combination with ZsTK474 or 
BeZ235 inhibits perK, paKT, and ps6 
expression
To determine if selumetinib in combination with ZSTK474 or 
BEZ235 can prevent both ERK and AKT signaling, pERK and 
pAKT expression levels were determined by western blotting 
1 and 24 h after 500 nM drug treatment (Figure 5). pAKT was 
investigated only at the ser473 phosphorylation site, since the 
basal expression at thr308 was too weak (Figure 2) to evaluate 
drug activity across the cell line panel. Treatment with selumetinib 
alone had no effect on pAKT expression, but was able to effectively 
inhibit pERK expression in all nine cell lines. By contrast, ZSTK474 
and BEZ235 both inhibited pAKT expression but were largely inef-
fective at inhibiting pERK. In combination, selumetinib with either 
ZSTK474 or BEZ235 inhibited both pAKT and pERK expressions 
in all cell lines. A similar extent of pAKT and pERK inhibition 
was present after 1 or 24 h incubation (data not shown) with all 
treatments in all cell lines tested.
Since pS6 expression can predict responsiveness to BRAF and 
MEK inhibitors in BRAF-mutant melanoma cells (25, 26), we 
also investigated pS6 expression after 1 or 24 h treatment with 
selumetinib, ZSTK474 and BEZ235 alone and in combination 
with three cell lines that were highly sensitive to selumetinib 
and vemurafenib (NZM3, NZM11, and NZM20) and three cell 
lines that were less sensitive (NZM6, NZM7, and NZM12). 
Selumetinib had little effect on pS6 1 h after treatment in all cell 
lines, but after 24 h treatment caused greater inhibition of pS6 
in the three highly sensitive lines (Figure 6). ZSTK474 inhibited 
pS6 after 1 h in NZM7 and NZM12, but this partially recovered 
FigUre 3 | combining ZsTK474 or BeZ235 with selumetinib has little 
effect on potency but increases maximal inhibition of cell proliferation. 
(a) EC50 values for selumetinib, ZSTK474, and selumetinib + ZSTK474 with 
combination interactions shown based on the CI values at EC50. (B) Maximum 
inhibition of cell proliferation relative to pretreatment after 72 h exposure to 
selumetinib, ZSTK474, or selumetinib + ZSTK474 at concentrations up to 
10 μM. (c) Growth profile for NZM34 cells treated with selumetinib, ZSTK474, 
or selumetinib + ZSTK474. (D–F) As for (a–c) but with BEZ235 replacing 
ZSTK474. Bars or symbols represent the mean ± SEM of n = 3–7. Statistical 
significance of differences between mean values was evaluated by one-way 
ANOVA with Dunnett’s multiple comparison analysis. *P < 0.05; **P < 0.01; 
***P < 0.001 relative to both single agent treatments. CI values <0.7 indicated 
synergy, 0.7–0.9 indicated weak synergy, 0.9–1.1 indicated additivity, 1.1–1.45 
indicated weak antagonism, and >1.45 indicated antagonism.
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with 24 h treatment. ZSTK474 was ineffective in the other cell 
lines. BEZ235 inhibited pS6 in all cell lines at 1 and 24 h as did the 
combination of BEZ235 with selumetinib. ZSTK474 combined 
with selumetinib inhibited pS6 at a greater extent than either 
single agent alone in all cell lines at either 1 or 24 h treatment, 
except NZM7.
inhibitors of individual Pi3K isoforms or mTOr 
can interact with selumetinib or Vemurafenib to 
induce increased inhibition of cell Proliferation
Since ZSTK474 and BEZ235 were able to interact synergistically 
at EC50 or induce greater reductions in maximal inhibition of cell 
proliferation in combination with selumetinib and vemurafenib 
in the cell line panel, we next investigated whether inhibitors 
of individual PI3K isoforms or mTOR could have a similar 
impact. NZM7, NZM12, NZM20, and NZM34 were treated 
with the p110α inhibitor A66, the p110β inhibitor TGX-221, 
the p110δ inhibitor idelalisib, the p110γ inhibitor AS-252424, 
or the mTORC1/2 selective inhibitor KU-0063794 alone or 
in combination with selumetinib or vemurafenib. The PI3K 
isoform-selective inhibitors were ineffective at inhibiting cell 
proliferation as single agents with EC50 values in excess of 10 μM 
for all inhibitors in all cell lines, except AS-252424 in NZM7 
(EC50 =  2.5 ±  0.6  μM) and NZM12 (EC50 =  5.9 ±  2.7  μM) 
(Figure 7A). By contrast, KU-0063794 more potently inhibited 
cell proliferation with EC50 values ranging from 0.6 ±  0.2 to 
1.1 ± 0.7 μM across the four cell lines. There was no synergistic 
interaction in potency when these agents were combined with 
selumetinib or vemurafenib, except for KU-0063794 with vemu-
rafenib in NZM7 cells, where strong synergy was observed 
(CI = 0.20 ± 0.05) (Figure 7B).
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Despite the lack of synergy in drug potency, significant 
increases in maximal growth inhibition at concentrations up 
to 10  μM were observed in NZM7 cells with combination 
therapy of selumetinib and A66, idelalisib, or AS-252424 
(P < 0.05) and in NZM7, NZM20, and NZM34 cells with selu-
metinib and KU-0063794 (P < 0.05) (Figure 7C). However, 
unlike with ZSTK474 or BEZ235 (Figures  3C,F and 4C,F), 
the increase in maximal growth inhibition induced by A66, 
idelalisib, or AS-252424 in combination with selumetinib 
was only observed with high-drug concentrations (data not 
shown). No significant changes in maximal growth inhibition 
were observed for any of the vemurafenib and PI3K isoform 
inhibitor combinations, but maximal growth inhibition was 
significantly increased by vemurafenib and KU-0063794 relative 
to either agent alone in NZM7 (P < 0.001) and NZM34 (P < 0.05) 
cells (Figure 7D).
FigUre 4 | Vemurafenib interacts with ZsTK474 or BeZ235 for 
enhanced antiproliferative activity. (a) EC50 values for vemurafenib, 
ZSTK474, and vemurafenib + ZSTK474 with combination interactions shown 
based on the CI values at EC50. (B) Maximum inhibition of cell proliferation 
relative to pretreatment after 72 h exposure to vemurafenib, ZSTK474, or 
vemurafenib + ZSTK474 at concentrations up to 10 μM. (c) Growth profile for 
NZM34 cells treated with vemurafenib, ZSTK474, or vemurafenib + ZSTK474. 
(D–F) As for (a–c) but with BEZ235 replacing ZSTK474. Bars or symbols 
represent the mean ± SEM of n = 3–7. Statistical significance of differences 
between mean values was evaluated by one-way ANOVA with Dunnett’s 
multiple comparison analysis. *P < 0.05; **P < 0.01 relative to both single 
agent treatments. CI values <0.7 indicated synergy, 0.7–0.9 indicated weak 
synergy, 0.9–1.1 indicated additivity, 1.1–1.45 indicated weak antagonism, and 
>1.45 indicated antagonism.
selumetinib and ZsTK474 or BeZ235 
synergistically inhibit Tumor growth in an 
nZM20 Xenograft Model
To determine if selumetinib can synergize with ZSTK474 or 
BEZ235 to prevent tumor growth in vivo, NZM20 cells were 
inoculated into NIH-III immunodeficient mice. The NZM20 
cell line was selected since it was sensitive to selumetinib 
(Figure 2A), showed additivity at EC50 and significant increases 
in maximal growth inhibition to ZSTK474 or BEZ235 in com-
bination with selumetinib (Figure 3) and reproducibly forms 
tumors in vivo. Once tumors were established at 150–200 mm3, 
animals were treated with 25  mg/kg selumetinib, 200  mg/kg 
ZSTK474, 15 mg/kg BEZ235, 25 mg/kg selumetinib + 200 mg/
kg ZSTK474, or 25 mg/kg selumetinib + 15 mg/kg BEZ235 by 
oral gavage daily for 14 days. These dose levels were selected 
as they were known to be well tolerated and to partially inhibit 
FigUre 5 | selumetinib (sel) in combination with BeZ235 or ZsTK474 inhibits paKT and perK expression in BRAF-mutant melanoma cell lines. Cells 
were treated with 500 nM of each compound as indicated for 1 h. Blots are representative images of two independent determinations.
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tumor growth or pAKT or pERK expression as single agents 
(36, 43, 44). ZSTK474 and BEZ235 were able to inhibit tumor 
growth by 21.8  ±  6.6 and 19.9  ±  8.3% relative to control, 
respectively, by day 14, but neither change reached statistical 
significance, while selumetinib significantly inhibited tumor 
growth by 37.9 ±  6.9% (P <  0.05) relative to control at day 
14 (Figures 8A,B). Both combination regimens synergistically 
inhibited tumor growth from day 2 (BEZ235 and selumetinib) 
or day 4 (ZSTK474 and selumetinib) onward, with significant 
TGIs of 75.8 ± 3.1% (P < 0.0001) and 59.0 ± 7.4% (P < 0.0001) 
relative to control at day 14 for selumetinib with BEZ235 and 
ZSTK474, respectively. Treatment with selumetinib and BEZ235 
prevented tumors from growing above baseline levels during 
the treatment period and at day 14 tumor size was significantly 
reduced from selumetinib (P < 0.05) or BEZ235 (P < 0.0001) 
treatment alone. All treatments were well tolerated over the 
dosing period, with minimal weight change seen in all groups 
(Figure 8C).
Discussion
The introduction of BRAF and MEK inhibitors into clinical practice 
has improved outcomes for patients with metastatic BRAF-mutant 
melanoma. However, both intrinsic and acquired resistances limit 
the use of these agents in the clinic (2, 3, 6). Combination therapy 
with BRAF and MEK inhibitors has proved beneficial in overcom-
ing ERK-dependent acquired resistance (5), but current strategies 
to overcome intrinsic resistance or to identify determinants of 
sensitivity are limited. Since signaling through the PI3K/AKT/
mTOR pathway has been implicated in intrinsic resistance to 
BRAF or MEK inhibitor therapy, we investigated if individual 
or pan isoform inhibitors of PI3K and/or mTOR could enhance 
the antitumor activity of BRAF/MEK inhibitors in BRAF-mutant 
melanoma cell lines that are sensitive to BRAF/MEK inhibition.
A panel of nine early passage BRAF-mutant metastatic melanoma 
cell lines that were developed and maintained at 5% oxygen tension to 
mimic physiological oxygen levels in the tumor microenvironment 
FigUre 6 | selumetinib (sel) in combination with BeZ235 or ZsTK474 
inhibits ps6 expression in BRAF-mutant melanoma cell lines that are 
highly sensitive (nZM3, nZM11, nZM20) or moderately sensitive 
(nZM6, nZM7, nZM12) to single agent selumetinib. Cells were treated 
with 500 nM of each compound as indicated for 1 or 24 h. Blots are 
representative images of two independent determinations.
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was selected that displayed a range of sensitivities to selumetinib 
and vemurafenib. All the cell lines were considered to be sensitive to 
BRAF or MEK inhibition, as intrinsically resistant cell lines typically 
have EC50 values in excess of 5 μM in response to BRAF or MEK 
inhibitors (19, 32, 45). Cells that were most sensitive to BRAF inhibi-
tion with vemurafenib were also sensitive to MEK inhibition with 
selumetinib, as has previously been reported (19) with the exception 
of NZM43, a V600K mutant line, which was nearly 100-fold more 
sensitive to MEK than BRAF inhibition. The cell lines that were 
most sensitive to BRAF or MEK inhibition expressed low levels 
of pAKT and EGFR and were wild type for PTEN. These results 
were largely expected since loss of functional PTEN (16), EGFR 
upregulation (46) and high basal expression of pAKT (18–20) have 
been implicated in resistance to BRAF and MEK inhibition.
Single agent therapy with selumetinib or vemurafenib was 
cytostatic in the majority of cell lines, being unable to inhibit cell 
proliferation to pretreatment levels, despite selumetinib achieving 
substantial reduction of pERK in excess of the 80% inhibition 
required for in vitro sensitivity and clinical activity (25, 47). This 
suggests that while ERK signaling was the main driver of growth 
in these cell lines, other signaling pathways also contributed. The 
exceptions were the highly sensitive NZM3 and NZM11 cells, where 
selumetinib and vemurafenib both induced a cytotoxic response on 
cell proliferation. Since these cells expressed low levels of pAKT, it 
is likely that they were highly dependent on ERK signaling and so 
BRAF or MEK inhibition alone was sufficient to prevent cell growth.
Combined MEK and BRAF inhibition has proven beneficial 
in the clinic to overcome ERK-dependent acquired resistance in 
BRAF-mutant melanoma patients (5). Here, synergy was observed 
in 7/9 BRAF-mutant cell lines when selumetinib and vemurafenib 
were applied in combination. However, the combination was less 
effective in cell lines that had low-pERK expression, where ERK 
signaling is less likely to play a major role in oncogenesis. Notably, 
maximum growth inhibition with selumetinib and vemurafenib in 
FigUre 7 | selumetinib and vemurafenib can interact with inhibitors of 
individual Pi3K isoforms or mTOr to cause minor changes in potency 
or maximal inhibition of cell proliferation. EC50 values for selumetinib (a) or 
vemurafenib (B) and PI3K isoform or mTOR inhibitors alone and in 
combination. (c) Maximum inhibition of cell proliferation relative to pretreatment 
after 72 h exposure to selumetinib or (D) vemurafenib and PI3K isoform or 
mTOR inhibitors alone and in combination at concentrations up to 10 μM. Bars 
represent the mean ± SEM of two to six independent evaluations. Arrows 
indicate EC50 values exceeded 10 μM. Statistical significance of differences 
between mean values was evaluated by one-way ANOVA with Dunnett’s 
multiple comparison analysis. *P < 0.05; **P < 0.01; ***P < 0.001 relative to 
both single agent treatments.
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combination was unchanged relative to both agents alone, largely 
because these agents targeted the same signaling pathway in the 
absence of ERK-dependent acquired resistance in this short duration 
cell proliferation model. As a result, combination therapy with selu-
metinib and vemurafenib remained cytostatic in several cell lines.
Inhibition of PI3K alone with ZSTK474 or PI3K and mTOR 
with BEZ235 was effective at inhibiting cell proliferation and AKT 
signaling in all BRAF-mutant melanoma cell lines. PI3K inhibitors 
have previously shown activity in melanoma, regardless of BRAF 
mutation status (32, 48), in response to PI3K family members 
being highly expressed in metastatic melanoma, and PTEN being 
frequently deleted (49). However, compensatory signaling through 
the RAS/RAF/MEK/ERK pathway following tyrosine kinase recep-
tor upregulation or pathway cross-talk can lead to resistance to 
PI3K inhibitors, particularly in BRAF-mutant melanoma where 
ERK signaling is enhanced, warranting the need for combination 
therapy (27–31). Synergy was observed for vemurafenib and 
ZSTK474 or BEZ235 combinations in several cell lines, but was 
less pronounced for selumetinib combinations, possibly due to 
the greater potency of selumetinib over vemurafenib as a single 
agent. However, in all cell lines, regardless of whether synergy 
was observed, treatment with selumetinib or vemurafenib in 
combination with either ZSTK474 or BEZ235 generated a cytotoxic 
response. Other than NZM3 and NZM11, where BRAF or MEK 
inhibition alone was sufficient for cytotoxicity, the remaining cell 
lines all benefited from dual inhibition with significantly greater 
maximal inhibition of proliferation with at least one of the BRAF/
MEK inhibitor and PI3K or PI3K/mTOR inhibitor combinations 
relative to each agent on their own. These results suggest that even 
BRAF or MEK inhibitor sensitive BRAF-mutant melanoma cell 
lines are not entirely dependent on ERK signaling for their growth. 
Cells that express pAKT can still proliferate in the absence of ERK 
signaling and so inhibition of both ERK and AKT signaling (as 
achieved by selumetinib and ZSTK474 or BEZ235 combinations) 
is required for cytotoxic inhibition of growth.
Isoform-selective inhibitors of PI3K lacked potency at inhibiting 
cell proliferation on their own, but A66, idelalisib, and AS-252424 
were able to significantly increase maximal inhibition when 
combined with selumetinib, but not vemurafenib, in NZM7 cells. 
However, since the isoform-selective PI3K inhibitors only enhanced 
selumetinib activity at concentrations approaching 10 μM, it is 
possible that these effects could be due to loss of isoform selectivity 
at these high concentrations. Nevertheless, the activity was less than 
that observed for ZSTK474, suggesting that although one or more 
of the PI3K isoforms may play a preferential role in promoting 
survival in BRAF-mutant melanoma cell lines, inhibition of all or 
most isoforms is required due to the ability of isoforms to readily 
compensate for one another (50, 51). This is consistent with our pre-
vious findings that isoform-selective PI3K inhibitors are ineffective 
at inhibiting pAKT expression on their own at low concentrations, 
except for p110α-selective inhibitors in H1047R PIK3CA mutant 
lines, but in combination can substantially inhibit pAKT expres-
sion (36). By contrast, KU-0063794 demonstrated strong synergy 
in combination with vemurafenib in NZM7 cells and increased 
maximal growth inhibition in NZM7, NZM20, and NZM34 cells 
with selumetinib or vemurafenib. By inhibiting mTORC1 and 2, 
KU-0063794 can prevent pS6 and pAKT expression (52) with pS6 
FigUre 8 | selumetinib (sel) in combination with ZsTK474 or BeZ235 
synergistically inhibits tumor growth in an nZM20 xenograft model. 
(a) Average tumor volume over the 14-day dosing period. (B) Tumor growth 
inhibition (TGI) at day 14. Statistical significance of differences between mean 
values was evaluated by one-way ANOVA with Sidak’s multiple comparison 
analysis. *P < 0.05; **P < 0.01; ***P < 0.001 relative to control. Statistically 
significant differences between treatment groups are marked as indicated. 
(c) Bodyweight changes over the 14-day dosing period. Bars and symbols 
represent the mean ± SEM (n = 7).
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treated with single agent BRAF or MEK inhibition, for the major-
ity of lines, enhancement of antitumor activity can be achieved by 
combining BRAF or MEK inhibition with an inhibitor of PI3K/
mTOR signaling to block ERK, AKT, and S6 signaling. Despite 
either inhibition of PI3K or mTOR synergizing with BRAF/
MEK inhibition, dual PI3K/mTOR inhibition appears the most 
promising strategy to enhance sensitivity to BRAF and MEK 
inhibition and possibly overcome ERK-independent intrinsic 
or acquired resistance.
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